bioGenous

Established in 2021 and based in Suzhou, China, bioGenous is a biotechnology company that focuses on cell technology development and application, human stem cell technology development and application, human gene diagnosis and therapy technology development. The company has a 3,000-square-meter R&D and production base, and three R&D and operation centers in Suzhou, Shanghai and Dezhou. In December 2024, it closed a series A+ funding from new investor China International Capital Corporation. The company provides production services such as organoid automation equipment, multi-tissue whole process kits, organoid culture and sample library construction technology solutions, organoid drug development and precision medicine subsystems.

Their self-developed products such as multi-disease models and new drug development platforms such as human-derived organoid new crown infection model, maternal cell tumorigenesis model, fully automated organoid library building and high-throughput drug screening platform, innovative organoid models based on tissue and tumor microenvironment analysis. The company generates revenue by researching biomedical sciences and developing drugs. The company will used the funds for developing markets in China and overseas, production base construction and innovative technology development.